Skip Navigation



Rheumatology Advance Access published online on November 1, 2005
Rheumatology, doi:10.1093/rheumatology/kei165
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
45/3/348    most recent
kei165v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mat, C.
Right arrow Articles by Yazici, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mat, C.
Right arrow Articles by Yazici, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received August 3, 2005
Accepted September 14, 2005

Original Articles

A double-blind trial of depot corticosteroids in Behçet's syndrome

C. Mat 1, S. Yurdakul 2*, S. Uysal 3, F. Gogus 4, Y. Ozyazgan 5, O. Uysal 6, I. Fresko 4, and H. Yazici 4

1 Department of Dermatology, University of Istanbul, Turkey; These authors contributed equally to this work
2 Division of Rheumatology, Department of Medicine, University of Istanbul, Turkey; These authors contributed equally to this work
3 Department of Dermatology, University of Istanbul, Turkey
4 Division of Rheumatology, Department of Medicine, University of Istanbul, Turkey
5 Department of Ophthalmology, University of Istanbul, Turkey
6 Department of Biostatistics, Behçet's Syndrome Research Centre, Cerrahpasa Medical Faculty, University of Istanbul, Turkey

* To whom correspondence should be addressed.
S. Yurdakul, E-mail: profsyurdakul{at}hotmail.com


  Abstract

Objectives. Corticosteroids are widely used in Behçet's syndrome despite the absence of controlled studies. We assessed the effect of depot corticosteroids primarily for genital ulcers and secondarily for the other mucocutaneous manifestations of Behçet's syndrome.

Methods. We randomized 86 patients who had active disease with genital ulcers to receive either intramuscular corticosteroid injections (40 mg methylprednisolone acetate) or placebo every 3 weeks for 27 weeks.

Results. Seventy-six patients (88%) completed the treatment. There were no significant differences in the mean number of genital and oral ulcers, or folliculitis between groups. The mean number of erythema nodosum lesions was less in the corticosteroid group as a whole (P=0.0046); subgroup analyses revealed that this was significant for females (P=0.0148) but not for males (P=0.1).

Conclusion. Low-dose depot corticosteroids did not have any beneficial effect on genital ulcers. However, it was useful in controlling erythema nodosum lesions, especially among the females.

Keywords: Behçet; Corticosteroids; Erythema nodosum; Genital ulcer; Therepy.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
P. P. Sfikakis, N. Markomichelakis, E. Alpsoy, S. Assaad-Khalil, B. Bodaghi, A. Gul, S. Ohno, N. Pipitone, M. Schirmer, M. Stanford, et al.
Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations
Rheumatology, May 1, 2007; 46(5): 736 - 741.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.